Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies

Psychopharmacology

Volumn 151, Issue 2-3, 2000, Pages 121-141

  Trujillo, K A ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Addiction; Analgesia; Excitatory amino acid; NMDA receptors; Opiate; Opioid; Physical dependence; Plasticity; Sensitization; Tolerance

Indexed keywords

2 AMINO 4,5 (1,2 CYCLOHEXYL) 7 PHOSPHONOHEPTANOIC ACID; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; EXCITATORY AMINO ACID; KYNURENIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADDICTION; ANALGESIA; BEHAVIOR; DRUG DEPENDENCE; DRUG EFFECT; HOT PLATE TEST; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSITIZATION; STATE DEPENDENT LEARNING; TAIL FLICK TEST;

EID: 0033847254     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000416     Document Type: Review

References (193)

1. Metaplasticity: The plasticity of synaptic plasticity
2. The competitive NMDA receptor antagonist LY235959 modulates the progression of morphine tolerance in rats
3. Time-dose relationships for locomotor activity effects of morphine after acute or repeated treatment
4. Persistence of chronic morphine effects upon activity in rats 8 months after ceasing the treatment
5. Morphine tolerance as habituation
6. Drug discrimination analysis of ethanol as an N-methyl-D-aspartate receptor antagonist
7. Evaluation of the reinforcing effects of eliprodil in rhesus monkeys and its discriminative stimulus effects in rats
8. Competitive and uncompetitive N-methyl-D-aspartate antagonist discriminations in pigeons: CGS 19755 and phencyclidine
9. Previous treatment with morphine and sensitization to the excitatory actions of opiates: Dose-effect relationship
10. NMDA-receptor-dependent synaptic plasticity in the visual cortex
11. Synaptic plasticity: LTP and LTD
12. Effects of NMDA receptor channel blockers, dizocilpine and memantine, on the development of opiate analgesic tolerance induced by repeated morphine exposures or social defeats in mice
13. The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat
14. Prolongation of morphine analgesia by competitive NMDA receptor antagonist D-CPPene (SDZ EAA 494) in rats
15. N-Methyl-D-aspartate receptor antagonists and the development of tolerance to the discriminitive stimulus effects of morphine in rats
16. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome, and self-administrative behavior
17. Dizocilpine (MK-801) blocks tolerance to the analgesic but not to the hyperthermic effect of morphine in the rat
18. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective μ or δ opioid agonists in mice
19. Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats
20. Pharmacological specificity of the discriminative stimulus properties of 2-amino-4,5-(l,2-cyclohexyl)-7-phosphono-heptanoic acid (NPC 12626), a competitive N-methyl-D-aspartate receptor antagonist
21. Locomotor behavior in morphine-dependent and post-dependent rats
22. Enhancement of the opiate withdrawal response by antipsychotic drugs in guinea pigs is not mediated by sigma binding sites
23. Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviors and increased hippocampal acetylcholine efflux in morphine-dependent rats
24. Differential behavioral and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats
25. Effects of ibogaine on the development of tolerance to antinociceptive action of mu-, delta- and kappa-opioid receptor agonists in mice
26. Excitatory amino acid receptor antagonists and naloxone-precipitated withdrawal syndrome in morphine-dependent mice
27. MK-801 disrupts the expression but not the development of bromocriptine sensitization: A state dependency interpretation
28. Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a mu opioid
29. ++ block of NMDA-receptor channels as a mechanism of modulation
30. Epidural morphine plus ketamine for upper abdominal surgery: Improved analgesia from preincisional versus postincisional administration
31. Contribution of central neuroplasticity to pathological pain: Review of clinical and experimental evidence
32. Excitatory amino acid receptors in the vertebrate central nervous system
33. Frequent colocalization of mu opioid and NMDA-type glutamate receptors at postsynaptic sites in periaqueductal gray neurons
34. Molecular and cellular mechanisms in opioid tolerance
35. Synaptic plasticity in ischemia: Role of NMDA receptors
36. Associative and non-associative tolerance to morphine: Support for a dual-process habituation model
37. Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications
38. Glutamate antagonists have different effects on spontaneous locomotor activity in rats
39. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia
40. Fear-potentiated startle: A neural and pharmacological analysis
41. Central acute pain mechanisms
42. Mixed depressant and stimulant actions of morphine and their relationship to brain acetylcholine
43. Concurrent spinal infusion of MK801 blocks spinal tolerance and dependence induced by chronic intrathecal morphine in the rat
44. Dextromethorphan attenuates and reverses analgesic tolerance to morphine
45. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids
46. Acute tolerance to spinally administered morphine compares mechanistically with chronically induced morphine tolerance
47. Procedures that produce context-specific tolerance to morphine in rats also produce context-specific withdrawal
48. N-Methyl-D-aspartate attenuates opioid receptor-mediated G protein activation and this process involves protein kinase C
49. Preemptive ketamine decreases postoperative narcotic requirements in patients undergoing abdominal surgery
50. Effect of activity at metabotropic, as well as ionotropic (NMDA), glutamate receptors on morphine dependence
51. Opioid tolerance and dependence: A new model highlighting the role of metabotropic glutamate receptors
52. Chronic morphine increases calbindin D28 k in-rat striatum: Possible NMDA receptor involvement
53. Effects of NMDA receptor antagonists in squirrel monkeys trained to discriminate the competitive NMDA receptor antagonist NPC 12626 from saline
54. Decrease of tolerance to, and dependence on morphine by, glutamate receptor antagonists
55. Preoperative dextromethorphan reduces intraoperative but not postoperative morphine requirements after laparotomy
56. Dual ultrastructural localization of mu-opioid receptors and NMDA-type glutamate receptors in the shell of the rat nucleus accumbens
57. Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists
58. MK-801 inhibits the development of morphine tolerance at spinal sites
59. The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus
60. Clinical medications development for opiate addiction: Focus on non-opioids and opioid antagonists for the amelioration of opiate withdrawal symptoms and relapse prevention
61. The effects of NMDA receptor antagonists and hitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development tissues for opiate addiction
62. The NMDA antagonist dizocilpine (MK-801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal
63. Nonpharmacological bases of drug tolerance and dependence
64. Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine
65. Dextromethorphan potentiates morphine antinociception, but does not reverse tolerance in rats
66. Modification by MK-801 (dizocilpine), a noncompetitive NMDA receptor antagonist, of morphine sensitization: Evaluation by ambulation in mice
67. Preclinical evidence for a role of glutamatergic systems in opioid tolerance and dependence
68. Is the discriminative stimulus produced by phencyclidine due to an interaction with N-methyl-D-aspartate receptors?
69. MK-801 prevents the development of behavioral sensitization during repeated morphine administration
70. Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants
71. Blockade of 'reverse tolerance' to cocaine and amphetamine by MK-801
72. Amphetamine sensitization and the excitatory amino acids
73. Context-specific morphine withdrawal in rats: Duration and effects of clonidine
74. The glycine site of the NMDA receptor - Five years on
75. The NMDA receptor antagonist MK-801 protects against the development of morphine tolerance after intrathecal administration
76. N-Methyl-D-aspartate antagonism and phencyclidine-like activity: A drug discrimination analysis
77. Peripheral blockade of topical morphine tolerance by ketamine
78. Topical opioids in mice: Analgesia and reversal of tolerance by a topical N-methyl-D-aspartate antagonist
79. 1 opioid analgesic tolerance by NPC17742, a novel NMDA antagonist
80. 1-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance
81. The treatment of heroin addicts with dextromethorphan. A double-blind comparison of dextromethorphan with chlorpromazine
82. Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats
83. Effects of MK-801 on morphine physical dependence: Attenuation and intensification
84. The importance of the number of NMDA receptors in the development of supersensitivity or tolerance to and dependence on morphine
85. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans
86. Acute tolerance associated with a single opiate administration: Involvement of N-methyl-D-aspartate-dependent pain facilitatory systems
87. Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time
88. Opiate tolerance to daily heroin administration: An apparent phenomenon associated with enhanced pain sensitivity
89. Effects of NMDA receptor antagonists on morphine tolerance: A c-Fos study in the lumbar spinal cord of the rat
90. The glycine site on the NMDA receptor: Structure-activity relationships and therapeutic potential
91. Prospects for clinically tolerated NMDA antagonists: Open channel blockers and alternative redox states of nitric oxide
92. The effect of MK-801 and SCH23390 on the expression and sensitization of morphine-induced oral stereotypy
93. The role of ketamine, an NMDA receptor antagonist, in the management of pain
94. Blockade of morphine-induced analgesia and tolerance in mice by MK-801
95. Blockade of morphine tolerance by ACEA-1328, a novel NMDA receptor/glycine site antagonist
96. Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test
97. ACEA-1328 a NMDA receptor/glycine site antagonist, acutely potentiates antinociception and chronically attenuates tolerance induced by morphine
98. Inhibitory effect of the NMDA receptor antagonist, dizocilpine (MK-801), on the development of morphine dependence
99. Effect of NMDA receptor antagonists on protein kinase activated by chronic morphine treatment
100. NMDA-receptor-dependent synaptic plasticity: Multiple forms and mechanisms
101. Continuous co-administration of dextromethorphan or MK-801 with morphine: Attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance
102. Pharmacological specificity of the phencyclidine discriminative stimulus in rats
103. Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C
104. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions
105. Increases in protein kinase C immunoreactivity in the spinal cord of rats associated with tolerance to the analgesic effects of morphine
106. Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats
107. Antinociceptive tolerance to the mu-opioid agonist DAMGO is dose-dependently reduced by MK-801 in rats
108. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat
109. Delayed application of MK-801 attenuates development of morphine tolerance in rats
110. mu-Opioid receptors modulate NMDA receptor-mediated responses in nucleus accumbens neurons
111. Chronic morphine treatment selectively augments metabotropic glutamate receptor-induced inhibition of N-methyl-D-aspartate receptor-mediated neurotransmission in nucleus accumbens
112. Mechanisms of opioid tolerance: A current view of cellular mechanisms
113. The association of neuropathic pain, morphine tolerance and dependence, and the translocation of protein kinase C
114. Antinociceptive potentiation and attenuation of tolerance by intrathecal co-infusion of magnesium sulfate and morphine in rats
115. Dextromethorphan and pain after total abdominal hysterectomy
116. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development
117. The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence
118. Effects of N-methyl-D-aspartate receptor antagonists on discriminative stimulus effects of naloxone in morphine-dependent rats using the Y-maze drug discrimination paradigm
119. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain
120. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging
121. Phencyclidine-like discriminative stimulus effects of polyamine modulators of N-methyl-D-aspartate receptor activity in rats
122. Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine
123. Memantine is a clinically well-tolerated N-methyl-D-aspartate (NMDA) receptor antagonists - A review of preclinical data
124. Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance
125. Conditioning as a critical determinant of sensitization induced by psychomotor stimulants
126. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine
127. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence
128. Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists
129. Homeostatic theory of drug tolerance: A general model of physiological adaptation
130. Analgesic agents for the postoperative period. Nonopioids
131. NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal
132. Excitatory amino acids and morphine withdrawal: Differential effects of central and peripheral kynurenic acid administration
133. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animals models of amphetamine psychosis
134. Therapeutic potential of excitatory amino acid antagonists: Channel blockers and 2,3-benzodiazepines
135. Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds
136. Postoperative pain: The effect of low-dose ketamine in addition to general anesthesia
137. Ketamine attenuates and reverses morphine tolerance in rats
138. Ethanol attenuation of morphine dependence: Comparison to dizocilpine
139. Pharmacological habituation and learning
140. Classical conditioning and opiate tolerance and withdrawal
141. The discriminative stimulus properties of (+)-HA-966, an antagonist at the glycine/N-methyl-D-aspartate receptor
142. Role of opioid receptors in narcotic tolerance/dependence
143. Pain analysis in patients with fibromyalgia: Effects of intravenous morphine, lidocaine, and ketamine
144. A glutamatergic hypothesis of drug dependence: Extrapolations from benzodiazepine receptor ligands
145. Neurobiology of conditioning to drugs of abuse
146. Tolerance and sensitization to the behavioral effects of drugs
147. Blockade of the development of morphine tolerance by U-50,488, and AVP antagonist or MK-801 in the rat hippocampal slice
148. Are NMDA receptors involved in tolerance and sensitization to the locomotor effects of morphine?
149. Acute behavioral interactions between opiates and NMDA receptor antagonists in rats
150. Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs
151. Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614
152. Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: Assessment of opioid receptor changes
153. The behavioral effects of MK-801: A comparison with antagonists acting non-competitively and competitively at the NMDA receptor
154. Effects of non-competitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence
155. Cellular and molecular mechanisms of of opioid tolerance and dependence: Progress and pitfalls
156. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801
157. Opiate tolerance and dependence: Recent findings and synthesis
158. Does MK-801 block naloxone-precipitated opiate withdrawal?
159. Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonists
160. Excitatory amino acids and drugs of abuse: A role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence
161. Tolerance, sensitization and physical dependence to the locomotor effects of morphine in rats
162. Does MK-801 affect the expression of opiate tolerance, sensitization or physical dependence
163. Inhibition of morphine tolerance and dependence by MK-801: Behavioral and neurochemical studies
164. Preemptive effect of fentanyl and ketamine on postoperative pain and wound hyperalgesia
165. Procedural examination of behavioral sensitisation to morphine: Lack of blockade by MK-801, occurrence of sensitised sniffing, and evidence for cross-sensitisation between morphine and MK-801
166. Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitization
167. Does the non-competitive NMDA receptor antagonist dizocilpine (MK-801) really block behavioral sensitization associated with repeated drug administration?
168. Tzschentke and Schmidt reply
169. Blockade of tolerance to stress-induced analgesia by MK-801 in mice
170. Does dizocilpine (MK-801) inhibit the development of morphine-induced behavioral sensitization in rats?
171. Dizocilpine (MK-801): Use or abuse
172. Tolerance development to the biphasic effects of morphine on locomotor activity and brain acetylcholine in the rat
173. 2 dopamine and N-methyl-D-aspartate (NMDA) receptors in morphine tolerance and dependence in mice
174. Mu-opioid and NMDA-type glutamate receptors are often colocalized in spiny neurons within patches of the caudate-putamen nucleus
175. Molecular mechanisms that underlie structural and functional changes at the postsynaptic membrane during synaptic plasticity
176. Sensory changes and pain after abdominal hysterectomy: A comparison of anesthetic supplementation with fentanyl versus magnesium or ketamine
177. Discriminative stimulus effects of site-selective N-methyl-D-aspartate antagonists in NPC 17742-trained rats and squirrel monkeys
178. Pentobarbital-like discriminative stimulus effects of N-methyl-D-aspartate antagonists
179. The behavioral pharmacology of NMDA receptor antagonists
180. Drug discrimination based on the competitive N-methyl-D-asparate antagonist, NPC 12626
181. Pentobarbital-like effects of N-methyl-D-aspartate antagonists in mice
182. MK-801 (dizocilpine): Synergist and conditioned stimulus in bromocriptine-induced psychomotor sensitization
183. Effects of strychnine-insensitive glycine receptor ligands in rats discriminating dizocilpine or phencyclidine from saline
184. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants
185. NMDA receptors and behavioral sensitization: Beyond dizocilpine
186. Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitization
187. Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: Binding at μ-opioid receptors
188. Pre-emptive analgesia with ketamine, morphine and epidural lidocaine prior to total knee replacement
189. Subunit- and site-specific pharmacology of the NMDA receptor channel
190. Discriminative stimulus effects of the NMDA receptor antagonists MK-801 and CGP 37849 in rats
191. NMDA-R1 antisense oligonucleotide attenuates withdrawal signs from morphine